# Combination of E-cigarettes and Varenicline for Tobacco Harm Reduction

> **NCT04210180** · PHASE2,PHASE3 · COMPLETED · sponsor: **Rose Research Center, LLC** · enrollment: 25 (actual)

## Conditions studied

- Smoking Cessation
- Harm Reduction

## Interventions

- **DRUG:** Varenicline
- **OTHER:** e-cigarette

## Key facts

- **NCT ID:** NCT04210180
- **Lead sponsor:** Rose Research Center, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-11-19
- **Primary completion:** 2020-10-14
- **Final completion:** 2021-03-22
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2022-02-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04210180

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04210180, "Combination of E-cigarettes and Varenicline for Tobacco Harm Reduction". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT04210180. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*